Testosterone-replacement therapy does not increase cardiac events in men with hypogonadism

Summary: Background: The cardiovascular safety of testosterone-replacement therapy in middle-aged and older men with hypogonadism was examined in a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial. Results showed that testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events, although a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism was observed in the testosterone group.